Galectin Therapeutic (GALT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 12-2018 | 12-2017 | 12-2016 | 12-2015 | 12-2014 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 8,253 | 3,053 | 15,362 | 25,846 | 29,128 |
| TOTAL | $8,832 | $3,819 | $15,794 | $26,400 | $29,661 |
| Non-Current Assets | |||||
| PPE Net | N/A | N/A | N/A | N/A | 1 |
| Intangibles | 0 | 0 | 1 | 8 | 15 |
| Other Non-Current Assets | 174 | 342 | 0 | 0 | 0 |
| TOTAL | $174 | $342 | $1 | $8 | $16 |
| Total Assets | $9,006 | $4,161 | $15,795 | $26,408 | $29,677 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 297 | 608 | 910 | 448 | 906 |
| Accrued Expenses | 1,512 | 2,292 | 2,802 | 845 | 729 |
| TOTAL | $2,108 | $2,968 | $3,780 | $1,360 | $1,703 |
| Non-Current Liabilities | |||||
| TOTAL | $N/A | $N/A | $N/A | $N/A | $N/A |
| Total Liabilities | $2,108 | $2,968 | $3,780 | $1,360 | $1,703 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 45,550 | 37,570 | 34,065 | 28,825 | 23,546 |
| Common Shares | 41 | 36 | 33 | 28 | 22 |
| Retained earnings | -196,215 | -181,168 | -163,701 | -140,049 | -118,925 |
| Other shareholders' equity | 8,942 | 8,962 | 8,962 | 7,565 | 7,346 |
| TOTAL | $6,898 | $1,193 | $12,015 | $25,048 | $27,974 |
| Total Liabilities And Equity | $9,006 | $4,161 | $15,795 | $26,408 | $29,677 |